The AstraZeneca share price carries a bullish daily bias, yet overbought readings make the distinction between trend support and entry timing important. Intraday positioning supports that bias. However, the 15-minute MACD sits below its signal line, leaving short-term confirmation mixed.
AZN — daily chart with candlesticks, EMA20/EMA50 and volume.
Key takeaways
AstraZeneca closed Friday, October 30, 2026 at $186.65 , a gain of 7.02% versus the previous close, on volume of 5,464,500 shares.
The close stands above the daily 20-session EMA at $168.84, the 50-session EMA at $166.56 and the 200-session EMA at $172.2, with the 200-session EMA above both shorter averages.
Daily RSI14 is 75.14 and hourly RSI14 is 79.3, both in overbought territory.
The 15-minute MACD line is 1.6, below its signal at 2.19, with a histogram of -0.58.
The next-session daily pivot is $186.05, with first resistance at $188.99 and first support at $183.7.
On Friday, October 30, 2026, AstraZeneca opened at $183.59 and traded between a low of $183.10 and a high of $188.39, and closed at $186.65 , against a previous close of $174.40. The session gained 7.02% versus the previous close, with volume of 5,464,500 shares .
AstraZeneca share price: daily strength without full EMA alignment
AstraZeneca’s close of $186.65 stands above its three daily EMAs, though the averages are not fully aligned. Price sits above the 20-session EMA at $168.84 , the 50-session EMA at $166.56 and the 200-session EMA at $172.2. That positioning supports the bullish case. At the same time, the 200-session EMA sits above both shorter averages, so the alignment is incomplete.
Daily RSI14 and MACD readings
Daily RSI14 stands at 75.14 , in overbought territory. MACD on the daily chart shows a line at 3.87, above its signal at 2.05, with a positive histogram of 1.82. Directional evidence therefore favors the bulls, while RSI flags an overbought condition rather than a bearish trigger by itself.
Bollinger envelope and daily ATR14
Meanwhile, the close also stands above the daily upper Bollinger band at $180.88, beyond the upper boundary of the daily volatility envelope. Daily ATR14 increased to $4.44 from $3.7 on the preceding candle, indicating a larger measured trading range.
AstraZeneca share price: hourly confirmation, mixed short-term timing
The close of $186.65 stands above all three hourly EMAs, so hourly readings confirm the daily direction. Price sits above the 20-hour EMA at $179.6 , the 50-hour EMA at $174.6 and the 200-hour EMA at $167.58. Those averages are aligned in bullish order beneath the close. Hourly RSI14 is 79.3 , also in overbought territory.
Nevertheless, the hourly MACD histogram declined to 1.2 from 1.42 on the preceding candle. It remains positive, with the MACD line at 4.36 above its signal at 3.16. That positive histogram keeps hourly confirmation in place, although the smaller reading qualifies it.
15-minute MACD and Bollinger levels
In contrast, the 15-minute MACD line is 1.6, below its signal at 2.19, with a negative histogram of -0.58 . The 15-minute RSI14 is 66.49, above 50 but below the overbought threshold. These readings complicate execution timing without overriding the daily bias.
Still, the session close sits above the 15-minute 20-period EMA at $185.86, but below the Bollinger mid-band at $186.99. It remains between the lower band at $186.13 and the upper band at $187.86. Those levels frame short-term positioning, and 15-minute ATR14 reads $0.74.
AstraZeneca restructuring report and earnings context
A Yahoo Finance report published during Friday’s session set out AstraZeneca’s three-year restructuring program. It targets $1.5 billion in annual benefits and up to $2 billion in charges. Those are reported program figures, not evidence that the targets have been achieved.
Separately, an earnings-call transcript published on Saturday, October 31, 2026, described oncology and rare disease momentum offsetting cardiovascular headwinds. That publication followed Friday’s session.
Bullish and bearish scenarios for the next session
When trading resumes, the daily pivot sits at $186.05 , with first resistance at $188.99 and first support at $183.7. The hourly pivot for the next session is $186.58, with first resistance at $187.04 and first support at $186.24. These are forward reference levels derived from each timeframe’s last completed candle.
Bullish scenario: holding the daily pivot at $186.05
The bullish scenario requires the AstraZeneca share price to hold the daily pivot at $186.05. Short-term confirmation would first require clearing the 15-minute Bollinger mid-band at $186.99 and hourly first resistance at $187.04. Clearing Friday’s high at $188.39 would then put price above the session’s upper boundary, ahead of daily first resistance at $188.99.
Bearish scenario: a break below the daily pivot
Conversely, a break below the daily pivot at $186.05 would weaken that setup. Daily first support at $183.7 comes next, followed by Friday’s low at $183.1. A break below that low would invalidate the immediate bullish continuation case. Below it sits the daily upper Bollinger band at $180.88.
Overall, the close at $186.65 leaves AstraZeneca above the next-session daily pivot but below Friday’s high and daily first resistance. Daily ATR14 at $4.44 frames the range risk. The unresolved question is whether bullish daily and hourly positioning can secure short-term confirmation, despite overbought readings and a negative 15-minute MACD histogram.
FAQ
Where does the AstraZeneca share price sit relative to its daily moving averages?
The close of $186.65 stands above the daily 20-session EMA at $168.84, the 50-session EMA at $166.56 and the 200-session EMA at $172.2. The averages are not fully aligned, because the 200-session EMA sits above both shorter averages.
What do the RSI14 and MACD readings show across timeframes?
Daily RSI14 is 75.14 and hourly RSI14 is 79.3, both in overbought territory. The daily MACD line is 3.87, above its signal at 2.05, while the 15-minute MACD line at 1.6 sits below its signal at 2.19.
Where does the close sit relative to the daily Bollinger band?
The $186.65 close stands above the daily upper Bollinger band at $180.88, beyond the upper boundary of the daily volatility envelope.
Which levels frame the next session?
The next-session daily pivot is $186.05, with first resistance at $188.99 and first support at $183.7. The hourly pivot for the next session is $186.58, with first resistance at $187.04 and first support at $186.24.
{“@context”:”https://schema.org”,”@type”:”FAQPage”,”mainEntity”:[{“@type”:”Question”,”name”:”Where does the AstraZeneca share price sit relative to its daily moving averages?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”The close of $186.65 stands above the daily 20-session EMA at $168.84, the 50-session EMA at $166.56 and the 200-session EMA at $172.2. The averages are not fully aligned, because the 200-session EMA sits above both shorter averages.”}},{“@type”:”Question”,”name”:”What do the RSI14 and MACD readings show across timeframes?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”Daily RSI14 is 75.14 and hourly RSI14 is 79.3, both in overbought territory. The daily MACD line is 3.87, above its signal at 2.05, while the 15-minute MACD line at 1.6 sits below its signal at 2.19.”}},{“@type”:”Question”,”name”:”Where does the close sit relative to the daily Bollinger band?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”The $186.65 close stands above the daily upper Bollinger band at $180.88, beyond the upper boundary of the daily volatility envelope.”}},{“@type”:”Question”,”name”:”Which levels frame the next session?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”The next-session daily pivot is $186.05, with first resistance at $188.99 and first support at $183.7. The hourly pivot for the next session is $186.58, with first resistance at $187.04 and first support at $186.24.”}}]}
Disclaimer: This article is for informational purposes only and does not constitute financial advice, an investment recommendation, or a solicitation to buy or sell any financial instrument. The analysis provided is not indicative of future results. Investing in financial markets carries a high risk of capital loss. Always do your own research (DYOR) and consult a qualified financial advisor before making any decision.
Cryptonomist and the author hold no positions in the financial instruments mentioned and receive no compensation from the companies covered.
Article produced with the assistance of artificial intelligence and reviewed by the editorial team.
